What is the trade name for methylphenidate (Extended Release) 18mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Trade Name for Methylphenidate ER 18 mg

The trade name for methylphenidate extended-release 18 mg is Concerta. 1

Formulation Details

Concerta is the brand name for the OROS (Osmotic Release Oral System) methylphenidate formulation available in 18 mg strength. 1 This represents the starting dose for children naïve to stimulant treatment and is equivalent to methylphenidate 5 mg given three times daily. 1

Key Characteristics of Concerta 18 mg:

  • Delivery mechanism: Uses an osmotic-release oral system (OROS) that produces an ascending-pattern plasma drug level through timed drug-delivery 1

  • Duration of action: Provides once-daily dosing with efficacy extending into the early evening (up to 12 hours post-dose) 1, 2

  • Pharmacokinetic profile: Contains 22% of the total daily dose as an immediate-release overcoat, with the remaining 78% delivered through the osmotic system 2

Other Methylphenidate ER Brand Names:

While Concerta is the specific answer for 18 mg ER formulation, other methylphenidate extended-release trade names include:

  • Ritalin SR (sustained release) 1
  • Ritalin LA (long-acting) 3
  • Biphentin 1
  • Foquest 1
  • Metadate CD (available in 20 mg, not 18 mg) 4, 2

Important Clinical Distinction:

Generic non-OROS formulations of methylphenidate ER are not therapeutically equivalent to brand-name Concerta, despite being labeled as "generic Concerta." 5 Studies demonstrate clinically significant differences in ADHD symptom control between OROS and non-OROS formulations at equivalent doses, with patients showing mean T-score reductions of 23 points on inattention scales when switched from non-OROS to OROS formulations. 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.